Skip to main content Skip to section navigation Skip to footer
Stock Information
chevron_leftBack to RenovoRx.com
RenovoRX, Inc. IR Overview
  • Investors
  • Company Info
    • Company Profile
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • News & Events
    • Press Releases
    • Clinical News
    • IR Calendar Events
    • Email Alerts
  • Financial Info
    • Financial Information Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • SEC Filings Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Stock Information
  • chevron_leftBack to RenovoRx.com

Press Releases

News & Events

  • Press Releases
  • Clinical News
  • IR Calendar Events
  • Email Alerts
Apr 4, 2025 8:30 am EDT
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
Apr 1, 2025 8:30 am EDT
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
Mar 28, 2025 8:00 am EDT
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
Mar 26, 2025 8:00 am EDT
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
Mar 20, 2025 8:00 am EDT
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET
Mar 19, 2025 8:00 am EDT
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
Feb 26, 2025 8:00 am EST
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
Feb 13, 2025 8:00 am EST
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
Feb 11, 2025 7:00 am EST
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
Feb 6, 2025 8:49 pm EST
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Page 18
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
©2026 RenovoRX, Inc. All Rights Reserved.
  • Privacy Policy
  • Terms of Use
  • Disclaimer
  • Sitemap
  • Accessibility Statement
  • Manage Cookie Preferences

Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.